Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843023 · ClinicalTrials.gov registry record · Phase 4
Extended Release Naltrexone for Opioid-Dependent Youth
A Phase 4 study, sponsored by Friends Research Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 288
- Enrollment target
NCT01843023 is a Phase 4 study that has completed, run by Friends Research Institute. The registered enrollment target is 288 participants.
The verdict
NCT01843023, a Phase 4 study, has completed, sponsored by Friends Research Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 288 participants
- Enrollment target
Study Summary
The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual (TAU).
Interventions
- DRUG Buprenorphine
- BEHAVIORAL Psychosocial Treatment
- DRUG Extended Release Naltrexone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2013-06 |
| Est. Completion | 2019-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01843023
The ClinicalTrials.gov registry entry for NCT01843023 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Friends Research Institute, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Buprenorphine is the first listed.
NCT01843023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01843023 about?
NCT01843023 is a clinical study titled "Extended Release Naltrexone for Opioid-Dependent Youth". The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual (TAU).
What is the current status of trial NCT01843023?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 288 participants. The study started on 2013-06. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01843023?
The interventions under investigation include: Buprenorphine (DRUG), Psychosocial Treatment (BEHAVIORAL), Extended Release Naltrexone (DRUG).
Who is sponsoring clinical trial NCT01843023?
This trial is sponsored by Friends Research Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.